[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100344596":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":50,"centralContacts":55,"locations":56,"responsibleParty":68,"collaborators":55,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":55,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":55,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":55,"overallStatus":90,"whyStopped":55,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","EXPERIMENTAL","Evogliptin→Evogliptin+Empagliflozin→Empagliflozin",[13],"Drug: Evogliptin→Evogliptin+Empagliflozin→Empagliflozin",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B","Empagliflozin→Evogliptin→Evogliptin+Empagliflozin",[18],"Drug: Empagliflozin→Evogliptin→Evogliptin+Empagliflozin",{"label":20,"type":10,"description":21,"interventionNames":22},"Group C","Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin",[23],"Drug: Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin",{"label":25,"type":10,"description":26,"interventionNames":27},"Group D","Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin",[28],"Drug: Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin",[30,37,41,46],{"type":31,"name":11,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD",[9],[35,36],"Suganon","Jardiance",{"type":31,"name":16,"description":38,"armGroupLabels":39,"otherNames":40},"Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD",[15],[35,36],{"type":31,"name":21,"description":42,"armGroupLabels":43,"otherNames":44},"Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD",[20],[35,45],"Forxiga",{"type":31,"name":26,"description":47,"armGroupLabels":48,"otherNames":49},"Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD",[25],[35,45],[51],{"name":52,"affiliation":53,"role":54},"Min soo Park, M.D., Ph.D.","Clinical Trial Center, Severance Hospital","PRINCIPAL_INVESTIGATOR",null,[57],{"facility":58,"status":55,"city":59,"state":55,"zip":60,"country":61,"countryCode":55,"cosmosGeoPoint":62,"geoPoint":67,"contacts":55},"Clinical Trials Center, Severance Hospital","Seoul","03722","South Korea",{"type":63,"coordinates":64},"Point",[65,66],126.9784,37.566,{"lat":66,"lon":65},{"type":69,"investigatorFullName":55,"investigatorTitle":55,"investigatorAffiliation":55,"oldNameTitle":55,"oldOrganization":55},"SPONSOR","100344596","phase-1-pharmacokinetic-and-pharmacodynamic-drug-drug-interaction-of-evogliptin-and-empagliflozin-or-dapagliflozin-in-healthy-male-adults-100344596",false,"NCT03766724","Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults","A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin 5 mg and Empagliflozin 25 mg or Dapagliflozin 10 mg After Oral Administration in Healthy Male Adults","Inclusion Criteria:\n\n* Health Male Volunteers (Age : 19\\~55 years)\n* Body Weight≥55kg, 18.5≤BMI\\\u003C25.0\n\nExclusion Criteria:\n\n* galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption\n* Allergy or Drug hypersensitivity\n* Clinically significant Medical History\n* AST, ALT \\> Upper Normal Range\\*1.25, eGFR\\\u003C60mL\u002Fmin\u002F1.73㎡\n* Drink during clinical trial period\n* Smoking during clinical trial period\n* Grapefruit\u002FCaffeine intake during clinical trial period\n* No Contraception",true,"MALE","19 Years","55 Years",{"count":82,"type":83},42,"ACTUAL","INTERVENTIONAL",[86],"PHASE1","A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin 5 mg and Empagliflozin 25 mg or Dapagliflozin 10 mg after Oral Administration in Healthy Male Adults",[89],"Type2 Diabetes","COMPLETED","2019-04-08",{"date":93,"type":83},"2019-04-10",{"date":95,"type":83},"2018-11-22",{"date":97,"type":83},"2019-01-18",{"name":5,"class":6},1]